Publication:
Paclitaxel carboplatin in elderly patients with advanced non-small cell lung cancer

No Thumbnail Available

Date

2012-07-01

Authors

Kanat, Özkan
Çubukcu, Erdem
Aksoy, Savas
Çubukcu, Sinem
Canhoroz, Mustafa
Karadağ, Oya
Alkış, Nihan
Manavoğlu, Osman

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

Derman Medical Publ

Research Projects

Organizational Units

Journal Issue

Abstract

Aim: In this study, the safety and tolerability of paclitaxel and carboplatin (PC) regimen in elderly patients with advanced non -small cell lung cancer (NSCLC) was investigated. Material and Method: Elderly patients (ages a70 years) who received PC for stage III (n=111 or IV (n=34) NSCLC were evaluated retrospectively. Results: There were 43 males and 2 females, with a median age of 75.5 (range, 70-62). The response rate was 40%. The median overall survival time and progression-free survival time was 13 months and 8.5 months, respectively. One-year survival rate was 51%. Treatment was well tolerated by the patients. The most frequent side effect observed was grade 3 or 4 neutropenia (57.795). There was no treatment related death. Discussion: PC regimen may be a good alternative for the treatment of elderly patients with advanced NSCLC.

Description

Keywords

Non-small cell, Lung, Elderly, Chemotherapy, Science & technology, Life sciences & biomedicine, Medicine, general & internal, General & internal medicine

Citation

Collections

0

Views

0

Downloads

Search on Google Scholar